Cargando…
Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy
Syngeneic, immunocompetent allograft tumor models recapitulate important aspects of the tumor microenvironment and have short tumor latency with predictable growth kinetics, making them useful for trialing novel therapeutics. Here, we describe surgical techniques for orthotopic and heterotopic pancr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078400/ https://www.ncbi.nlm.nih.gov/pubmed/29903803 http://dx.doi.org/10.1242/dmm.034793 |
_version_ | 1783345085937614848 |
---|---|
author | Erstad, Derek J. Sojoodi, Mozhdeh Taylor, Martin S. Ghoshal, Sarani Razavi, Allen A. Graham-O'Regan, Katherine A. Bardeesy, Nabeel Ferrone, Cristina R. Lanuti, Michael Caravan, Peter Tanabe, Kenneth K. Fuchs, Bryan C. |
author_facet | Erstad, Derek J. Sojoodi, Mozhdeh Taylor, Martin S. Ghoshal, Sarani Razavi, Allen A. Graham-O'Regan, Katherine A. Bardeesy, Nabeel Ferrone, Cristina R. Lanuti, Michael Caravan, Peter Tanabe, Kenneth K. Fuchs, Bryan C. |
author_sort | Erstad, Derek J. |
collection | PubMed |
description | Syngeneic, immunocompetent allograft tumor models recapitulate important aspects of the tumor microenvironment and have short tumor latency with predictable growth kinetics, making them useful for trialing novel therapeutics. Here, we describe surgical techniques for orthotopic and heterotopic pancreatic ductal adenocarcinoma (PDAC) tumor implantation and characterize phenotypes based on implantation site. Mice (n=8 per group) were implanted with 10(4) cells in the pancreas or flank. Hy15549 and Han4.13 cell lines were derived from primary murine PDAC (Ptf1-Cre; LSL-KRAS-G12D; Trp53 Lox/+) on C57BL/6 and FVB strains, respectively. Single-cell suspension and solid tumor implants were compared. Tumors were treated with two intravenous doses of FOLFIRINOX and responses evaluated. All mice developed pancreatic tumors within 7 days. Orthotopic tumors grew faster and larger than heterotopic tumors. By 3 weeks, orthotopic mice began losing weight, and showed declines in body condition requiring euthanasia starting at 4 weeks. Single-cell injection into the pancreas had near 100% engraftment, but solid tumor implant engraftment was ∼50% and was associated with growth restriction. Orthotopic tumors were significantly more responsive to intravenous FOLFIRINOX compared with heterotopic tumors, with greater reductions in size and increased apoptosis. Heterotopic tumors were more desmoplastic and hypovascular. However, drug uptake into tumor tissue was equivalent regardless of tumor location or degree of fibrosis, indicating that microenvironment differences between heterotopic and orthotopic tumors influenced response to therapy. Our results show that orthotopic and heterotopic allograft locations confer unique microenvironments that influence growth kinetics, desmoplastic response and angiogenesis. Tumor location influences chemosensitivity to FOLFIRINOX and should inform future preclinical trials. This article has an associated First Person interview with the first author of the paper. |
format | Online Article Text |
id | pubmed-6078400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Company of Biologists Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-60784002018-08-07 Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy Erstad, Derek J. Sojoodi, Mozhdeh Taylor, Martin S. Ghoshal, Sarani Razavi, Allen A. Graham-O'Regan, Katherine A. Bardeesy, Nabeel Ferrone, Cristina R. Lanuti, Michael Caravan, Peter Tanabe, Kenneth K. Fuchs, Bryan C. Dis Model Mech Research Article Syngeneic, immunocompetent allograft tumor models recapitulate important aspects of the tumor microenvironment and have short tumor latency with predictable growth kinetics, making them useful for trialing novel therapeutics. Here, we describe surgical techniques for orthotopic and heterotopic pancreatic ductal adenocarcinoma (PDAC) tumor implantation and characterize phenotypes based on implantation site. Mice (n=8 per group) were implanted with 10(4) cells in the pancreas or flank. Hy15549 and Han4.13 cell lines were derived from primary murine PDAC (Ptf1-Cre; LSL-KRAS-G12D; Trp53 Lox/+) on C57BL/6 and FVB strains, respectively. Single-cell suspension and solid tumor implants were compared. Tumors were treated with two intravenous doses of FOLFIRINOX and responses evaluated. All mice developed pancreatic tumors within 7 days. Orthotopic tumors grew faster and larger than heterotopic tumors. By 3 weeks, orthotopic mice began losing weight, and showed declines in body condition requiring euthanasia starting at 4 weeks. Single-cell injection into the pancreas had near 100% engraftment, but solid tumor implant engraftment was ∼50% and was associated with growth restriction. Orthotopic tumors were significantly more responsive to intravenous FOLFIRINOX compared with heterotopic tumors, with greater reductions in size and increased apoptosis. Heterotopic tumors were more desmoplastic and hypovascular. However, drug uptake into tumor tissue was equivalent regardless of tumor location or degree of fibrosis, indicating that microenvironment differences between heterotopic and orthotopic tumors influenced response to therapy. Our results show that orthotopic and heterotopic allograft locations confer unique microenvironments that influence growth kinetics, desmoplastic response and angiogenesis. Tumor location influences chemosensitivity to FOLFIRINOX and should inform future preclinical trials. This article has an associated First Person interview with the first author of the paper. The Company of Biologists Ltd 2018-07-01 2018-07-30 /pmc/articles/PMC6078400/ /pubmed/29903803 http://dx.doi.org/10.1242/dmm.034793 Text en © 2018. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/3.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Research Article Erstad, Derek J. Sojoodi, Mozhdeh Taylor, Martin S. Ghoshal, Sarani Razavi, Allen A. Graham-O'Regan, Katherine A. Bardeesy, Nabeel Ferrone, Cristina R. Lanuti, Michael Caravan, Peter Tanabe, Kenneth K. Fuchs, Bryan C. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy |
title | Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy |
title_full | Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy |
title_fullStr | Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy |
title_full_unstemmed | Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy |
title_short | Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy |
title_sort | orthotopic and heterotopic murine models of pancreatic cancer and their different responses to folfirinox chemotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078400/ https://www.ncbi.nlm.nih.gov/pubmed/29903803 http://dx.doi.org/10.1242/dmm.034793 |
work_keys_str_mv | AT erstadderekj orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT sojoodimozhdeh orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT taylormartins orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT ghoshalsarani orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT razaviallena orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT grahamoregankatherinea orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT bardeesynabeel orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT ferronecristinar orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT lanutimichael orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT caravanpeter orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT tanabekennethk orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy AT fuchsbryanc orthotopicandheterotopicmurinemodelsofpancreaticcancerandtheirdifferentresponsestofolfirinoxchemotherapy |